NASDAQ:QURE

uniQure Stock Forecast, Price & News

$29.16
-0.58 (-1.95 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.84
$30.24
50-Day Range
$26.01
$37.17
52-Week Range
$25.80
$52.19
Volume413,459 shs
Average Volume434,016 shs
Market Capitalization$1.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
30 days | 90 days | 365 days | Advanced Chart
Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.


uniQure logo

About uniQure

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.97 out of 5 stars

Medical Sector

304th out of 2,214 stocks

Pharmaceutical Preparations Industry

152nd out of 869 stocks

Analyst Opinion: 4.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure
or view top-rated stocks.

What stocks does MarketBeat like better than uniQure?

Wall Street analysts have given uniQure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but uniQure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for uniQure
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Sunday, July, 25th. The biotechnology company reported $8.51 EPS for the quarter, topping the Zacks' consensus estimate of $2.97 by $5.54. uniQure had a negative trailing twelve-month return on equity of 57.38% and a negative net margin of 366.00%.
View uniQure's earnings history
.

How has uniQure's stock price been impacted by COVID-19 (Coronavirus)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QURE stock has decreased by 38.7% and is now trading at $29.16.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for QURE?

14 equities research analysts have issued 12-month target prices for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they anticipate uniQure's stock price to reach $60.88 in the next twelve months. This suggests a possible upside of 108.8% from the stock's current price.
View analysts' price targets for uniQure
or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:
  • Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 49, Pay $965.48k)
  • Mr. Christian Klemt, Chief Accounting Officer (Age 48, Pay $392.6k)
  • Dr. Alexander E. Kuta Ph.D., Exec. VP of Operations (Age 61, Pay $652.58k)
  • Dr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 52, Pay $626.15k)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Mr. Pierre Caloz, Chief Operating Officer
  • Mr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 54)
  • Ms. Maria E. Cantor, Chief Communications Officer (Age 53)
  • Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. Director
  • Mr. James Brady, Chief HR Officer

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Who are some of uniQure's key competitors?

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $29.16.

How much money does uniQure make?

uniQure has a market capitalization of $1.34 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125,020,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.